Abstract: The invention relates to new indazole derivatives, processes for their preparation, and their use in medicaments.

Abstract: The invention relates to a kit comprising a pharmaceutical composition containing repinotan or a physiologically acceptable salt of repinotan, and a means for the determination of the concentration of repinotan or its metabolites in body fluids, and also new pharmaceutical compositions containing repinotan or a physiologically acceptable salt of repinotan, and processes for their preparation.

Abstract: The invention relates to novel 3-oxo-2,1-benzisomazol-1(3H)-carboxamides (I), where R1, R2 are the same or different and independently=H, halogen, C1 C6 alkyl C1 C6 alkoxy, C1 C3 perfluoroalkyl, or a group NR5R6; R3, R4 are the same or different and independently=C1 C8 alkyl, whose carbon chain is optionally interrupted by an O, S or NR7 and is optionally singly or severally substituted by C3 C6 cycloalkyl, C1 C4 alkoxy, OH, halogen or NR8R9; C3 C8 cycloalkyl whose carbon chain is optionally interrupted by an O, S or NR10 and is optionally singly or severally substituted by C1 C4 alkoxy, OH, halogen or NR11R12, or R3 and R4 together with a nitrogen atom form a saturated or partially unsaturated 3- to 10-membered mono- or bi-cyclic heteocycle, which, optionally, contains up to two further heteroatoms, from N, O or S and is, optionally, substituted by C1 C4 alkyl, C1 C4 alkoxy, OH, halogen, COOR13 or NR14R15 and X=O or S.

Abstract: The present invention relates to a new substituted benzimidazoles, their preparation and their use as agents against parasitic protazoa.

Abstract: The present invention relates to stable quick-release extrudates that contain low-viscosity hydroxypropylcellulose and at least one active ingredient. This invention also relates to a method for preparing said extrudates without the use of solvents as well as to the use of said extrudates in the production of quick-release preparations.

Abstract: Disclosed herein is a self-zeroing dosage syringe comprising: (a) a syringe barrel which forms a volume sufficient to contain a required dosage of a fluid, a discharge end at one end of the barrel length, a plunger receiving end at the opposite end of the barrel length, (b) said plunger is movably disposed within the barrel and has a length greater than the length of the barrel, and further has at a set of multiple closely spaced indentations disposed along the length thereof, and (c) a movable dosage selection ring which is disposed around the plunger and rotatable about the longitudinal axis of the plunger; characterized in that the dosage selection ring has (1) a sleeve disposed inside the barrel, (2) a calibration on the sleeve thereof for setting the desired dosage by turning the ring until the calibration for a desired dose is reached, (3) a means for engaging the ring with the plunger allowing it to be moved cooperatively with the plunger until the ring dead ends against the syringe barrel thereby rele

Abstract: The present application relates to novel potent PPAR-alpha-activating compounds for treating, for example, coronary heart disease, and to their preparation.

Abstract: The present invention relates to novel amino acid esters of arylsulphonamides and analogues, to processes for their preparation and to their use for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy, craniocerebral trauma, pain and spasticity.

Abstract: The invention relates to novel isocyanates containing tertiary amino groups, a process for preparing them, and also their use for the synthesis and modification of polymers. The invention provides isocyanates of the formula (I) where R1 and R2 are, independently of one another, alkyl having from 1 to 6 carbon atoms, where R1 and R2 may be joined to form a ring, Z is alkylene having from 2 to 6 carbon atoms, n is an integer from 0 to 20, Y is alkylene having from 2 to 6 carbon atoms. The alkyl radicals R1 and R2 may be linear or branched or joined to form an aliphatic ring. The alkylene radical Z preferably contains from 2 to 4 carbon atoms.

Abstract: The present invention relates to the combination of the 3-hydroxy-3-methylglutaryl-coenzyme A inhibitor (HMG-CoA inhibitor) cerivastatin with fibrates and its use in the prophylaxis and treatment of disorders of lipid metabolism.

Abstract: The present invention relates to the construction and use of expression plasmids in the manufacture of recombinant interleukin-4 (IL-4) and interleukin-4 muteins.

Abstract: The present invention relates to novel arylsulphonamides and analogues, to processes for their preparation and to their use for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy, craniocerebral trauma, pain and spasticity.

Abstract: The present invention relates to novel substituted (&agr;,&bgr;-fused butyrolactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.